High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm

Figures & data

Table 1. Demographics of the study group.

Diagnosis	No. of patients	Median CA 19-9 level (i.q.r.)	Median age (i.q.r.)	Male/Female
Pancreatic cancer	49	148 kU/l (30–358 kU/l)	68 (64–71)	24/25
Stage 1B	9
Stage 2A	3
Stage 2B	14
Stage 3	22
Stage unknown	1
IPMN	13	10 kU/l (8.9–21 kU/l)	65 (43–72)	5/8
Mixed-type	12
Main duct	1
Healthy	47	6.9 kU/l (4.5–8.8 kU/l)	60 (56–63)	32/15

IPMN: intraductal papillary mucinous neoplasm.

Figure 1. Diagnostic performance of CA 19-9, IL.17E, B7.1 and DR6 for discrimination of pancreatic cancer and healthy controls.

Table 2. Best models for pancreatic cancer versus healthy.

Panel	Pancreatic cancer vs. healthy					Pancreatic cancer stage 1 vs. healthy
	AUC	sens80 (%)	sens90 (%)	R^2	maxp	AUC	sens80 (%)	sens90 (%)
CA 19-9 + IL.17E + B7.1 + DR6	0.974	95.9	95.9	0.812	0.02662	0.988	100	100
CA 19-9 + B7.1	0.953	91.8	91.8	0.728	0.0576	0.988	100	100
CA 19-9	0.903	87.8	85.7	0.662	0.00256	0.972	100	88.9
CA 19-9 + Eotaxin.2 + DR6	0.946	93.9	89.8	0.746	0.04775	0.939	88.9	88.9
IL.17E + B7.1 + DR6	0.830	69.4	59.2	0.379	0.00338	0.870	77.8	55.6
Eotaxin.2 + DR6	0.704	57.1	49	0.185	0.01029	0.679	55.6	55.6

maxp: highest individual p-value; sens80: sensitivity at 80% specificity; sens90: sensitivity at 90% specificity.

Figure 2. Diagnostic performance of CA 19-9, Eotaxin.2, CD163 and BMP.3b for discrimination of IPMN and healthy controls.

Table 3. Best models for IPMN versus healthy.

Panel	Pancreatic cancer and IPMN vs. healthy					IPMN vs. healthy
	AUC	sens80 (%)	sens90 (%)	R^2	Maxp	AUC	sens80 (%)	sens90 (%)
CA 19-9 + Eotaxin.2 + CD163 + BMP.3b	0.947	95.2	83.9	0.717	0.02213	0.915	92.3	53.9
CA 19-9 + B7.1	0.921	87.1	79	0.630	0.02701	0.812	69.2	38.5
B7.1	0.732	58.1	30.6	0.172	0.00694	0.771	76.9	7.7
CA 19-9	0.870	77.4	74.2	0.543	0.00423	0.747	38.5	30.8

maxp: highest individual p-value; sens80: sensitivity at 80% specificity; sens90: sensitivity at 90% specificity.

Figure 3. Diagnostic performance of B7.1 for discrimination of IPMN and healthy controls.

Figure 4. Diagnostic performance of CA 19-9, IL.17E, B7.1 and IL.12RBeta2 for discrimination of pancreatic cancer and IPMN.

Table 4. Best models for pancreatic cancer versus IPMN.

Panel	Pancreatic cancer vs. IPMN and healthy			R^2	maxp	Pancreatic cancer vs. IPMN
	AUC	sens80 (%)	sens90 (%)			AUC	sens80 (%)	sens90 (%)
CA 19-9 + IL.17E + B7.1 + IL.12RBeta2	0.922	91.8	89.8	0.633	0.00467	0.832	79.6	38.8
CA 19-9	0.876	85.7	85.7	0.461	0.0001	0.778	69.4	26.5

maxp: highest individual p-value; sens80: sensitivity at 80% specificity; sens90: sensitivity at 90% specificity.